GMP

Epicore Biosystems Partners With 3M and Innovize to Scale Development of its Sweat-Sensing Wearable Technology

Retrieved on: 
Thursday, September 29, 2022

CAMBRIDGE, Mass., Sept. 29, 2022 /PRNewswire/ -- Epicore Biosystems, a digital health company developing advanced sweat-sensing wearables to provide real-time personalized hydration insights for performance and safety, today announced a new collaboration with 3M's (NYSE: MMM) Health Care Business, a manufacturer and distributor of medical products and solutions, and Innovize Inc. (Innovize), a custom medical device manufacturer. Leveraging 3M's leading skin-interfacing materials and Innovize's manufacturing capabilities, Epicore Biosystems will further scale its portfolio of advanced wearable hydration solutions.

Key Points: 
  • Leveraging 3M's leading skin-interfacing materials and Innovize's manufacturing capabilities, Epicore Biosystems will further scale its portfolio of advanced wearable hydration solutions.
  • Epicore Biosystems has built a nimble network of domestic partners to effectively deploy its sweat-sensing technology as rising temperatures intensify the risk of dehydration among athletes and industrial workers in high-heat environments.
  • "Our collaboration with 3M and Innovize ensures that Epicore Biosystems has a strong domestic production infrastructure," said Jeffrey Model, chief product officer and co-founder at Epicore Biosystems.
  • Epicore Biosystems' product development incorporates materials and design strategies created in collaboration with Innovize to support high volume manufacturing.

Discovery Life Sciences Appoints Chief Scientific Officer to Drive Company's Rapid Global Expansion of Biomarker Services

Retrieved on: 
Thursday, September 29, 2022

HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.

Key Points: 
  • HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.
  • Dr. Platero brings over two decades of executive leadership in building and managing biomarker development organizations at leading pharmaceutical and diagnostics companies.
  • Before joining Discovery, Dr. Platero served as vice president of biomarkers, imaging, and diagnostics at Vertex Pharmaceuticals.
  • "Discovery is uniquely dedicated to providing scalable, end-to-end solutions for clients to accelerate their precision oncology programs," said Dr. Platero.

Discovery Life Sciences Appoints Chief Scientific Officer to Drive Company's Rapid Global Expansion of Biomarker Services

Retrieved on: 
Thursday, September 29, 2022

HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.

Key Points: 
  • HUNTSVILLE, Ala., Sept. 29, 2022 /PRNewswire/ -- Discovery Life Sciences (Discovery), the Biospecimen and Biomarker Specialists, announced that Suso J. Platero, Ph.D. ,has joined the company as its chief scientific officer.
  • Dr. Platero brings over two decades of executive leadership in building and managing biomarker development organizations at leading pharmaceutical and diagnostics companies.
  • Before joining Discovery, Dr. Platero served as vice president of biomarkers, imaging, and diagnostics at Vertex Pharmaceuticals.
  • "Discovery is uniquely dedicated to providing scalable, end-to-end solutions for clients to accelerate their precision oncology programs," said Dr. Platero.

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Retrieved on: 
Thursday, September 29, 2022

Earlier this year, Pluri signed a landmark collaboration agreement with Tnuva Group, Israels largest food producer to establish a cultivated food platform based on Pluris technology.

Key Points: 
  • Earlier this year, Pluri signed a landmark collaboration agreement with Tnuva Group, Israels largest food producer to establish a cultivated food platform based on Pluris technology.
  • Today, I am pleased to announce an additional technology collaboration, this time in the biologics industry.
  • We have entered a collaboration agreement with one of the worlds leading manufacturers of specialty biologic APIs for liver and gastroenterological diseases.
  • Over the past few months, we have made significant cost reductions to align our business with our new strategy.

Brains Bioceutical Opens UK’s Largest EU GMP-Grade Licensed Cannabinoid Research and Commercial Production Facility

Retrieved on: 
Thursday, September 29, 2022

VANCOUVER, British Columbia and SANDWICH, United Kingdom, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp (Brains or the Company), is pleased to announce the opening of its recently completed EU-GMP cannabinoid manufacturing facility.

Key Points: 
  • VANCOUVER, British Columbia and SANDWICH, United Kingdom, Sept. 29, 2022 (GLOBE NEWSWIRE) -- Brains Bioceutical Corp (Brains or the Company), is pleased to announce the opening of its recently completed EU-GMP cannabinoid manufacturing facility.
  • Our companys commitment to clinical research around efficacy and safety continue to remain the main force behind our teams commitment and growth, said Brains Chairperson and CEO, Ricky Brar.
  • By having one the largest EU GMP grade cannabinoid R&D and commercial facilities, we have positioned Brains Bio to be the number one supplier of safe, natural cannabinoid APIs, our team has set the highest and most stringent production standards in the industry.
  • Brains Bios market-leading position is further enhanced by its regulatory package, which includes:
    Over 350 commercial batches manufactured with resulting batch consistency and standardization data.

Board of Directors Approves Half-Year Financial Report as of June 30, 2022

Retrieved on: 
Wednesday, September 28, 2022

In the same period, liquidity increased from 92,593 thousand as of March 31, 2022 to 98,339 thousand as of June 30, 2022, showing an increase of approximately 6.2%.

Key Points: 
  • In the same period, liquidity increased from 92,593 thousand as of March 31, 2022 to 98,339 thousand as of June 30, 2022, showing an increase of approximately 6.2%.
  • Current and non-current financial debt decreased from 16,248 thousand as of March 31, 2022, to 16,225 thousand as of June 30, 2022, showing a decrease of approximately 0.14% resulting from the progress of existing amortization schedules.
  • Opening of new centers in Germany, Spain, Italy and Poland for the European Phase III study of first-line soft tissue sarcoma.
  • The Board of Directors approved the Group Sustainability Brochure, referring to the year 2021, which will be published on the Company's website ( https://www.philogen.com) in the "Governance" section.

e2e Pharma Announces NSF Certification of Phoenix, AZ Manufacturing Facility

Retrieved on: 
Wednesday, September 28, 2022

Phoenix, AZ, Sept. 28, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- e2e Pharma, a private label end-to-end manufacturer for CBD and non-CBD branded topicals and ingestibles that are sold direct to consumers online and through nationwide retail chains, announced today the certification of their 30,000-square-foot manufacturing facility, which has been audited and approved by NSF.

Key Points: 
  • e2e has achieved the 455-2GMP - NSF/ANSI 455-2 Good Manufacturing Practices for Dietary Supplements and the 455-3GMP - NSF/ANSI 455-3 Good Manufacturing Practices for Cosmetics.
  • Our mission at e2e Pharma continues to be based in safety, transparency, product efficacy, and trust, said Shannon Bard, Founder of e2e.
  • With decades of CPG experience informing our strategy, our team always strives for the highest standards in manufacturing practices, and our NSF certification is another third-party accolade that sets the products e2e creates ahead of the pack.
  • The NSF/ANSI 455 GMP mark indicates that an NSF auditor has audited a facility, checked documents and deemed the facility compliant with GMP regulations for production, said David Trosin, Managing Director, Global Health Sciences Certification at NSF.

Monrol Will Establish a Legal Entity and Manufacturing Facility in Germany

Retrieved on: 
Wednesday, September 28, 2022

Following an ongoing assessment of its entire operation, Eczacba-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.

Key Points: 
  • Following an ongoing assessment of its entire operation, Eczacba-Monrol Nuclear Products Co. (Monrol) has decided to establish a legal entity and manufacturing facility in Germany.
  • The facility will also have a dedicated division for state-of-the art cGMP Contract Development and Manufacturing Organization (CDMO) services.
  • Monrol plans to make the site a center of excellence for both radiopharmaceutical production and scientific and industry collaborative efforts to create innovations.
  • The facility is expected to be up and running by 2026 at an estimated cost of around 30 million euros.

Managing and Optimizing Clinical Supply in the Clinical Trial Market in China, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 28, 2022

TORONTO , Sept. 28, 2022  /PRNewswire-PRWeb/ -- China has become an important destination for clinical trials. What are the trends and challenges when conducting clinical trials in China? What are the important considerations to successfully supply clinical trials in China? This webinar will highlight the latest developments of the clinical trial industry in China and share experiences to optimize clinical supply chain in China. The featured speakers will discuss how to put together a strategy and solution that can work best for supply chain and logistics in the clinical trial market in China.

Key Points: 
  • The featured speakers will discuss importing into China and what to consider when conducting clinical research in China.
  • This webinar will highlight the latest developments of the clinical trial industry in China and share experiences to optimize clinical supply chain in China.
  • Register to learn more about managing and optimizing clinical supply in China.
  • For more information, or to register for this event, visit Managing and Optimizing Clinical Supply in the Clinical Trial Market in China .

Advanced Instruments Introduces Solentim VIPS™ PRO, A High Efficiency Single Cell Seeder to Optimize Cell Line Development Workflows

Retrieved on: 
Wednesday, September 28, 2022

NORWOOD, Mass., Sept. 28, 2022 /PRNewswire/ -- Advanced Instruments today announced the launch of Solentim VIPS PRO, a high efficiency single cell seeder, at the BioProcess International Conference in Boston, Massachusetts. VIPS PRO revolutionizes cell line development (CLD) and GMP manufacturing by combining powerful seeding technology with two-step, image-based proof of monoclonality and proprietary Artificial Intelligence-driven cell recognition for increased productivity and confidence.

Key Points: 
  • NORWOOD, Mass., Sept. 28, 2022 /PRNewswire/ --Advanced Instruments today announced the launch of Solentim VIPS PRO , a high efficiency single cell seeder, at the BioProcess International Conference in Boston, Massachusetts.
  • VIPS PRO revolutionizes cell line development (CLD) and GMP manufacturing by combining powerful seeding technology with two-step, image-based proof of monoclonality and proprietary Artificial Intelligence-driven cell recognition for increased productivity and confidence.
  • Based on the original VIPS technology, VIPS PRO is an indispensable technology for bringing innovative biotherapeutics to market.
  • VIPS PRO is part of an ecosystem of technologies from Advanced Instruments built to accelerate cell line development workflows, from initial discovery to scale-up and manufacturing of biotherapeutics.